5 unknown, 4 not yet recruiting, 3 recruiting, 1 active not recruiting. 14 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Unknown 5, Not yet recruiting 4, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer CDK4/6 inhibitor, Endocrine Therapy (Optional) - Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fudan University | 494 | 2026-09-15 | 2026-09-17 |
| Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Becotatug Vedotin - Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Kai Hu | 140 | 2026-09-01 | 2026-06-09 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC Sintilimab - Non-Small Cell Lung Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Sichuan University | 100 | 2025-01-10 | 2026-08-05 |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Guo Xufeng | 73 | 2023-09-07 | 2023-09-28 |
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery SOX, XELOX, PD-1 antibody - MSI-H, PD-1 Immunotherapy | Phase 2 | Active not recruiting | Fudan University | 94 | 2022-08-01 | 2026-08-11 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer Paclitaxel, Trastuzumab, Docetaxel - HER2-positive Breast Cancer, Adjuvant Therapy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2022-01-31 | 2022-01-12 |
| TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection TQB2450 injection, Anlotinib hydrochloride capsules - Hepatocellular Carcinoma, Adjuvant Therapy | Phase 2 | Unknown | Xianhai Mao | 37 | 2022-01-06 | 2022-05-04 |
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer Ensatinib, chemotherapy - ALK Fusion Protein Expression, Adjuvant Therapy | Phase 2 | Not yet recruiting | Sichuan University | 152 | 2022-01-01 | 2022-01-11 |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection Tislelizumab, TACE - Hepatocellular Carcinoma, Adjuvant Therapy | Phase 2 | Unknown | Zhejiang University | 50 | 2021-11-08 | 2022-01-05 |
| Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab - Stomach Neoplasms, Esophagogastric Junction Disorder | Phase 2 | Terminated | Fudan University | 6 | 2021-09-28 | 2025-06-18 |
| Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab - Breast Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 206 | 2021-07-02 | 2022-03-23 |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations Tirelizumab - Immunotherapy, Adjuvant Therapy | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2021-06-01 | 2021-07-20 |
| NAC Followed by RH for the Treatment of LACC Two cycles of neoadjuvant chemotherapy, First imaging evaluation, Second imaging evaluation - Neoadjuvant Chemotherapy, Locally Advanced Cervical Cancer | Phase 2 | Unknown | Lei Li | 60 | 2019-06-19 | 2019-06-20 |
Breast Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Nasopharyngeal Carcinoma (1) · Recurrence (1)
Neoplasms (12) · Neoplasms by Site (12) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Breast Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2)
Trastuzumab (2) · sintilimab (2) · tislelizumab (2) · Albumin-Bound Paclitaxel (1) · Anastrozole (1) · Carboplatin (1) · Chemoradiotherapy (1) · Docetaxel (1) · Drug Therapy (1) · Immunotherapy (1) · Letrozole (1) · Oxaliplatin (1) · Paclitaxel (1) · Protons (1) · Tamoxifen (1)
Fudan University (3) · Sichuan University (2) · Fujian Cancer Hospital (1) · Fujian Medical University Union Hospital (1) · Guo Xufeng (1) · Kai Hu (1) · Lei Li (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Xianhai Mao (1) · Zhejiang University (1)
China (11)
Changqing Pan (1) · Lei Li, M.D. (1) · Meijuan Huang, MD (1) · Tao Pan (1) · Yi Ba, MD (1) · You Lu, MD (1)
PMID 24419108, PMID 26028255, PMID 28241187, PMID 29727332, PMID 31513484, PMID 32251400, PMID 34160577, PMID 35764956